Drug use-related stigma, safer injection norms, and hepatitis C infection among a network-based sample of young people who inject drugs.
Drug use-related stigma, safer injection norms, and hepatitis C infection among a network-based sample of young people who inject drugs.
复制标题
DOI:
10.1016/j.drugalcdep.2021.108626
复制
发表时间:
2021-04-01
影响因子:
4.2
通讯作者:
Boodram B
中科院分区:
文献类型:
--
作者:
Williams LD;Mackesy-Amiti ME;Latkin C;Boodram B
Identifying risk for hepatitis C (HCV) infection is important for understanding recent increases in HCV incidence among young people who inject drugs (PWID) in suburban and rural areas; and for refining the targeting of effective HCV preventive interventions. Much of the extant research has focused on individual health behaviors (e.g., risky drug injection behaviors) as predictors of HCV infection. The present study examines two social factors (substance use-related stigma and injection-related social norms), and the interaction between these factors, as predictors of HCV infection. Baseline data were used from an ongoing longitudinal study of young PWID (N=279; mean age = 30.4 years) from the Chicago suburbs and their injection risk network members. Adjusted logistic regression models were used to examine relationships among substance use-related stigma, safer injection norms, and HCV infection. Despite a marginal bivariate association between less safe injection norms and HCV infection (OR=0.74; 95% CI[0.39, 1.02]; p=.071), a significant stigma X norms interaction (AOR=0.68; 95% CI[0.51, 0.90]) suggested that at high levels of stigma, probability of HCV infection was high regardless of injection norms. Findings suggest that social factors – specifically, substance use-related stigma and injection norms - are important predictors of HCV infection risk. The interaction found between these social factors suggests that intervening only to change injection norms or behaviors is likely insufficient to reduce risk for HCV infection in high-stigma settings or among high-stigma populations. Future research should develop and evaluate stigma-reduction interventions in combination with safer-injection interventions in order to maximize HCV risk reduction.
登录
查看更多内容
DOI:
10.1038/oby.2012.12
发表时间:
2012-05
期刊:
Obesity (Silver Spring, Md.)
影响因子:
--
作者:
Fettich KC;Chen EY
通讯作者:
Chen EY
影响因子:
3.7
作者:
Eckhardt B;Winkelstein ER;Shu MA;Carden MR;McKnight C;Des Jarlais DC;Glesby MJ;Marks K;Edlin BR
通讯作者:
Edlin BR
DOI:
10.1016/j.ejon.2011.06.008
发表时间:
2012-07
期刊:
European journal of oncology nursing : the official journal of European Oncology Nursing Society
影响因子:
--
作者:
Cataldo JK;Jahan TM;Pongquan VL
通讯作者:
Pongquan VL
影响因子:
3.3
作者:
Ironson G;Fitch C;Stuetzle R
通讯作者:
Stuetzle R
影响因子:
4.2
作者:
Latkin, Carl;Srikrishnan, Aylur K.;Yang, Cui;Johnson, Sethulakshmi;Solomon, Sunil S.;Kumar, Suresh;Celentano, David D.;Solomon, Suniti
通讯作者:
Solomon, Suniti